CAS No.171500-79-1, Dalbavancin

Indication of Acute Bacterial Skin and Skin Structure Infections

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) pose a significant healthcare challenge worldwide, affecting millions of individuals each year. These infections, ranging from cellulitis to wound infections, can lead to serious complications if not promptly and effectively treated. According to the Centers for Disease Control and Prevention (CDC), ABSSSI accounted for approximately 3.7 million emergency department visits in the United States alone in 2018, underscoring the need for advanced treatment options.

Dalbavancin Hydrochloride, one of our premier active pharmaceutical ingredients (API), offers a powerful solution for the treatment of ABSSSI. Extensive clinical studies have demonstrated its effectiveness against a broad spectrum of bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin Hydrochloride has shown superior outcomes in treating ABSSSI compared to standard therapies, making it a valuable asset in addressing the challenges posed by these infections.

Mechanism of Action

Dalbavancin Hydrochloride belongs to a class of antibiotics known as lipoglycopeptides, which are highly effective against Gram-positive bacteria. By targeting the bacterial cell wall synthesis, Dalbavancin inhibits the growth of susceptible pathogens and impairs their ability to proliferate. This mechanism of action ensures potent and sustained antibacterial activity, making Dalbavancin a formidable weapon against ABSSSI.

What sets Dalbavancin Hydrochloride apart is its extended half-life, enabling the administration of a single dose regimen. This convenience not only improves patient compliance but also reduces the burden on healthcare systems. Dalbavancin Hydrochloride's unique mechanism of action and dosing regimen make it an attractive option for global pharmaceutical companies seeking innovative solutions for the management of ABSSSI.

At Unibest, we are dedicated to providing high-value APIs like Dalbavancin Hydrochloride and its intermediates to our esteemed clients in the global pharmaceutical industry. Contact us today to explore how our pharmaceutical development and manufacturing services can help you bring this exceptional active pharmaceutical ingredient to the market efficiently and maximize its value. Together, let us combat ABSSSI and contribute to a healthier future.

Dalbavancin is produced through semi-synthesis. The starting material, illustrated as A-40926 (CAS No. 110882-84-3), can be produced by Nonomuria spp. through fermentation.